Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-001094-58 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Janssen Research & Development, LLC | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Balloon angioplasty (Percutaneous Coronary Intervention (PCI)) is commonly used to treat patients with obstructive coronary artery disease (CAD). Although PCI is highly effective for the management of CAD, it can potentiate an existing prothrombotic state around lesion areas. A certain level of anticoagulation is required to perform planned PCI safely and to minimize the periprocedural risk of thrombosis and its attendant complications, including myocardial ischemia and infarction (heart attack). Many different anti-thrombotic regimens have been investigated and are currently in use. The aim of this study is to explore whether Rivaroxaban, as compared to unfractionated heparin, on the background of standard dual antiplatelet therapy, can effectively suppress thrombosis and related adverse ischemic events, upon balloon inflation and stent expansion, during elective PCI, without increasing bleeding. The treatment assignment will be done in a semi-blinded design, eg, no blinding for randomization either to Rivaroxaban (one of the three arms) or the control (UFH) group. However, all will be blinded for the treatment dose of rivaroxaban (either 10mg or 20 mg).The 10 mg rivaroxaban plus 50 IU UFH arm will not be blinded.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Active Comparator |
| |
| Arm 2 | Experimental |
| |
| Arm 3 | Experimental |
| |
| Arm 4 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| UFH | Drug | Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds |
|
| Measure | Description | Time Frame |
|---|---|---|
| The percentage of subjects who require bail-out anticoagulant therapy in the context of an ischemic coronary event | During the index Percutaneous Coronary Intervention procedure | |
| The percentage of subjects who experience an angiographic flow limiting thrombotic event | During the index Percutaneous Coronary Intervention procedure | |
| The percentage of subjects who experience thrombus formation on the Percutaneous Coronary Intervention equipment | During the index Percutaneous Coronary Intervention procedure | |
| The percentage of subjects who experience an Myocardial Infarction due to the Percutaneous Coronary Intervention equipment procedure | During the index Percutaneous Coronary Intervention procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Bleeding (Thrombolysis in Myocardial Infarction major, minor and Bleeding academic research consortium type 2, 3 and 5) | Up to 30 days post index Percutaneous coronary intervention procedure | |
| Composite of clinical ischemic events (all death, non-fatal Myocardial Infarction, non-fatal stroke and target lesion revascularization |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hasselt | 3500 | Belgium | ||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25925992 | Result | Vranckx P, Leebeek FW, Tijssen JG, Koolen J, Stammen F, Herman JP, de Winter RJ, van T Hof AW, Backx B, Lindeboom W, Kim SY, Kirsch B, van Eickels M, Misselwitz F, Verheugt FW. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial. Thromb Haemost. 2015 Aug;114(2):258-67. doi: 10.1160/TH15-01-0061. Epub 2015 Apr 30. |
| Label | URL |
|---|---|
| Click here to find information about studies related to Bayer Healthcare products conducted in Europe | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Rivaroxaban (Xarelto, BAY59-7939) | Drug | 10 mg single dose Rivaroxaban (per os) |
|
| Rivaroxaban (Xarelto, BAY59-7939) | Drug | 20 mg single dose Rivaroxaban (per os) |
|
| Rivaroxaban (Xarelto, BAY59-7939) and UFH | Drug | 10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH) |
|
| Up to 30 days post index Percutaneous coronary intervention procedure |
| Coagulation profile of Rivaroxaban (Activated Partial Thromboplastin Time) | 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) |
| Coagulation profile of Rivaroxaban (Prothrombin time) | 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) |
| Coagulation profile of Rivaroxaban (Thrombin Time) | 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) |
| Coagulation profile of Rivaroxaban (Prothrombin Fragment 1+2) | 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) |
| Coagulation profile of Rivaroxaban (Thrombin Anti-thrombin III Complexes) | 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) |
| Coagulation profile of Rivaroxaban (Anti-Xa Activity) | 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) |
| Coagulation profile of Rivaroxaban (endogenous thrombin potential) | 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) |
| Plasma concentration of Rivaroxaban | The day of percutaneous coronary intervention (PCI) (from 2 to 4 hours before to 6-8 hours after PCI) |
| Liège |
| 4000 |
| Belgium |
| Roeselare | 8800 | Belgium |
| Amsterdam | 1091 AC | Netherlands |
| Amsterdam | 1105 AZ | Netherlands |
| Eindhoven | 5623 EJ | Netherlands |
| Zwolle | 8011 JW | Netherlands |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069552 | Rivaroxaban |
| ID | Term |
|---|---|
| D013876 | Thiophenes |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D009025 | Morpholines |
| D010078 | Oxazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided